clinical trial · NCT04475549
Phase 2a Study of IW-6463 in Adults Diagnosed With Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS)
MELASIW-6463 Tablets
brief summary
This is a single-arm study to evaluate safety and tolerability of oral IW-6463 in adults diagnosed with MELAS.
started
Nov 13, 2020
primary completion
Jan 23, 2022
completion
Jan 23, 2022
last updated
Aug 29, 2024
detailed description
IW-6463 tablets will be orally administered once-daily (QD) for up to 29 days
official title
A Phase 2a Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Individuals With Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol